New York, June 3, 2026, 06:04 EDT
Incyte Corp INCY stock slipped 3.5% Tuesday and kept sliding in premarket trading Wednesday, hit after new lymphoma data from its frontMIND trial. Shares finished at $92.24, down from $95.59 on Monday. About 2.02 million shares traded. Still, some analysts are sticking with their bullish calls on the name.
Incyte’s data are key right now, as the company tries to show it can expand outside of Jakafi, its top seller, ahead of a possible loss of exclusivity that opens the door to cheaper rivals. Biotech stocks slumped too: the SPDR S&P Biotech ETF dropped 4.39% Tuesday.
Nasdaq hadn’t started its regular session at the time. The market opens from 9:30 a.m. to 4:00 p.m. Eastern, and premarket begins at 4:00 a.m. June 3 is not on Nasdaq’s 2026 U.S. holiday calendar.
Incyte said the Phase 3 frontMIND trial looked at tafasitamab and lenalidomide with R-CHOP chemotherapy in people with newly diagnosed high-risk diffuse large B-cell lymphoma, or DLBCL. The cancer is aggressive. Adding the two drugs cut the risk of progression or death by 25%. Incyte said these results back its plans to file for approval worldwide.
Steven Stein, chief medical officer at Incyte, called the data a “potential inflection point” and said the company plans to move forward with global filings. Georg Lenz, the study’s lead investigator from University Hospital Münster, said the combination could “broaden the first-line treatment options.” Business Wire
Analysts were split on the news. Citizens kept a Market Perform on the stock, calling the shares fairly valued. They also pointed to more belief that Incyte’s portfolio might plug the gap from a ruxolitinib patent loss over $3 billion expected by late 2028.
Bank of America Securities analyst Tazeen Ahmad kept a Buy on the stock and left the target price at $124, pointing to the plan to expand the ex-Jakafi portfolio and the expected wave of 2026 clinical catalysts, TipRanks said. Barclays is still at Buy, with a $117 target, according to the same report.
H.C. Wainwright’s Mitchell Kapoor kept a Buy on the stock and held the $135 target, saying Monjuvi results back Incyte’s push to diversify past Jakafi. But he also pointed to execution and clinical risk and said some of the upside depends on whether later results show a lasting benefit.
Roche’s Polivy regimen is the main competitor. Roche said Polivy with R-CHP is cleared for first-line DLBCL in over 90 countries. Analysts are comparing Incyte’s frontMIND data to the POLARIX benchmark.
Incyte said the risk isn’t small. Interim overall survival—a measure of how long patients lived—only showed a positive trend and failed to reach statistical significance. The tafasitamab-lenalidomide-R-CHOP arm saw a higher rate of serious or severe treatment-emergent adverse events compared to R-CHOP alone. Fatal events tied to treatment were also more common in the combination group, though total deaths were lower there.
Investors are weighing if the market is cutting biotech risk or just skeptical about the move from trial wins to sales. Incyte posted first-quarter revenue up 21% at $1.27 billion. Jakafi net sales climbed 7% to $758 million, while Opzelura added 20% to reach $143 million. That brings in cash, but with Jakafi still the main story, questions remain on what’s next.
Shares are now stuck in a tight range. The pipeline case is stronger than a week ago, but the market still wants more certainty on approval timing, physician uptake and safety. Investors will find out at Wednesday’s open if Tuesday’s drop was just general biotech pressure or something more specific for Incyte’s outlook.
